- Home
- LBTYB vs FOLD Comparison
LBTYB vs FOLD Comparison
Compare LBTYB & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYB | FOLD |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | Bermuda | United States |
| Employees | 6636 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.5B |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | LBTYB | FOLD |
|---|---|---|
| Price | $14.39 | $14.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.25 |
| AVG Volume (30 Days) | 12.8K | ★ 2.5M |
| Earning Date | 02-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.41 | $20.50 |
| Revenue Next Year | $3.03 | $18.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.29 | $5.66 |
| 52 Week High | $29.01 | $14.50 |
Technical Indicators
Market Signals| Indicator | LBTYB | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 74.18 |
| Support Level | $10.09 | $14.21 |
| Resistance Level | $18.00 | N/A |
| Average True Range (ATR) | 1.34 | 0.02 |
| MACD | -0.23 | -0.00 |
| Stochastic Oscillator | 26.18 | 100.00 |
Price Performance
Historical ComparisonAbout LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.